Neisvac-C (Tetanus Toxoid, Algeldrate, N. Meningitidis Group C (Strain C11) Polysaccharide (De-O-Acetylated))

The tetanus toxoid component stimulates a T‑cell‑dependent immune response that generates neutralizing antibodies against tetanus toxin. The de‑O‑acetylated group C polysaccharide induces a T‑cell‑independent response, producing antibodies that target the meningococcal capsule. Algeldrate acts as an adjuvant to enhance the overall immune reaction.

The dosage and schedule of Neisvac-C are determined by the prescribing healthcare professional based on age, immunization history, and local guidelines. The vaccine is supplied as a lyophilized powder that is reconstituted and given as a single intramuscular injection.

Safety data for Neisvac-C in pregnancy are limited. It should be administered only if the expected benefit to the mother outweighs any potential risk to the fetus, and the decision should be made by a qualified health professional. Breastfeeding is not a contraindication, but consultation with a clinician is advised.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, cold‑chain shipping details and any necessary import documentation.

Neisvac-C combines tetanus toxoid with a de‑O‑acetylated group C polysaccharide, whereas some alternatives may include additional meningococcal serogroups or use conjugated polysaccharides. The choice depends on regional disease prevalence, immunization schedules, and regulatory approvals. Both provide protection against tetanus, but Neisvac-C focuses specifically on group C meningococcal disease.

Neisvac-C must be stored refrigerated at 2‑8 °C. It should be kept in its original packaging, protected from light, and must not be frozen or shaken. After reconstitution, the vaccine should be used promptly according to the manufacturer’s instructions.

Neisvac-C is supplied as a lyophilized powder that is reconstituted with a sterile diluent. The reconstituted solution is injected intramuscularly, typically into the deltoid muscle of adults or the anterolateral thigh of infants and young children, following aseptic technique.

The most serious adverse events reported with Neisvac-C include severe allergic reactions such as anaphylaxis, Guillain‑Barré syndrome, and rare neurologic complications like seizures. Immediate medical attention is required if any signs of a severe reaction occur after vaccination.

Neisvac-C should not be given to individuals with a known hypersensitivity to tetanus toxoid, algeldrate, or the meningococcal group C polysaccharide. It is also contraindicated in persons who have experienced a severe allergic reaction to a previous dose of the same vaccine.